Actually, the Cd17 trial is running really well. It's been the financial noose around the companies neck, which has been holding it back. The cause of that problem I have written about many times.
Dr Bec has found a fix for the financials to get us past a potential partnership point. And that point in time is now fast approaching.
Having Miles on board not only strengthens the companies team but also adds synergy to the drug development.
Soon, we get to the binary decision of if we get a partnership or not.
Very high risk. But this is the best position CHM has been in for many years.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)